Skip to main content
PolicySpeak
← All files
SOL

Solventum

Company · Belgium · EU Transparency Register 777082895009-31

2
positions filed
in the 326 files tracked
1
legislative file
of 326 tracked
0
with a full position paper
attached to a submission

Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.

Who they are

Among the 925 companies & groups on this site, they rank #554 by legislative files engaged — a count of participation, not a measure of influence.

0.6
declared lobbying FTE
self-declared
€200K+
declared costs / yr (floor)
0
EP accreditations
as declared to the register
2024
in the register since

Declares membership of

  • Solventum is a member of a number of associations, including but not limited to the American Chamber of Commerce to t…

Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).

Register category
Companies & groups
Registered as
KCI Medical Belgium BV / Solventum (Solventum)
Head office
Peer, Germany
EU office
Diegem

Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.

Track Solventum in PolicySpeak: request access →

Work at Solventum? so we know who speaks for it.

Follow the file Solventum engages with

One email on Tuesdays when a new position is filed on this file, from Solventum or from anyone else on it. Only when there is something new.

We use your email for these updates, and PolicySpeak may contact you about the product. Unsubscribe in one click. Privacy policy.

Their record over time

Solventum filed 2 positions between 6 Oct 2025 and 31 Jul 2026, across 1 of the 326 legislative files tracked here.

2025 · 1 filed2026 · 1 filed

What they argued

Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislationfiled 31 Jul 2026source

Solventum is a global medical technology company with over 22,000 employees worldwide, including around 4,000 in Europe. It develops solutions in wound care, oral healthcare and digital health. The proposed MDR revision is a positive step toward greater efficiency, predictability, and proportionality. Additional refinements are required to support patient safety and timely access to innovation. 1.

Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislationfiled 6 Oct 2025source

Solventum welcomes the opportunity to submit this input, in response to the European Commissions public consultation on the targeted revision of EU rules for medical devices and in vitro diagnostics. Implementation complexity of the Medical Devices Regulation (MDR), inconsistent interpretations by Notified Bodies (NBs) and lengthy approval timelines are delaying patient access to critical technologies.

Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.

Is this your organization?

Everything on this page comes from Solventum’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.

Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.